Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Valneva SE (AYJ.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
12.70-1.61 (-11.28%)
At close: 09:58PM CEST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close14.31
Open14.86
Bid13.01 x 125000
Ask13.05 x 125000
Day's Range12.36 - 15.18
52 Week Range7.25 - 30.50
Volume4,979
Avg. Volume5,712
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Valneva Announces Successful Outcome of its AGM and Appointment of two New Supervisory Board Members

    Saint-Herblain (France), June 24, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting (AGM) held yesterday in Paris. Among the adopted resolutions were approval of the 2021 financial statements, delegations for the management board to increase Valneva’s share capital and/or issue financial instruments, and the appointment, fo

  • Motley Fool

    Why Dynavax Crushed the Market on Thursday

    Biotech Dynavax Technologies (NASDAQ: DVAX) had a terrific Thursday on the stock market. Thursday morning, Valneva announced that the committee for medicinal products for human use (CHMP) advising the European Medicines Agency (EMA) has recommended the jab be granted marketing authorization as a primary shot for adults 18 to 50 years old. The next step is for the European Commission (EC) to review the CHMP's recommendation and make a decision.

  • GlobeNewswire

    Valneva and Pfizer Announce Closing of Equity Investment

    Saint-Herblain (France) and New York, June 23, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today announced the closing of the equity investment announced on June 20, 2022.1 Pursuant to an Equity Subscription Agreement, Pfizer has invested €90.5 ($95) million in Valneva, representing 8.1% of Valneva’s share capital at a price of €9.49 per share, through a reserved capital increase. Valneva is planning to use the proceeds to suppo

Advertisement
Advertisement